(Q33994406)

English

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

A F Hezel

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

M S Noel

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

J N Allen

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

T A Abrams

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

M Yurgelun

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

J E Faris

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

L Goyal

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

J W Clark

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

L S Blaszkowsky

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

J E Murphy

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

H Zheng

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

G C Connolly

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

O Hyrien

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

M Herr

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

K Ng

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

S Sheehan

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

D J Harris

19

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

E Regan

20

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

D R Borger

21

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

A J Iafrate

22

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

C Fuchs

23

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

D P Ryan

24

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

A X Zhu

25

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

0 references

publication date

24 June 2014

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

111

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

430-436

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

https://scigraph.springernature.com/pub.10.1038/bjc.2014.343

0 references

A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Cancer statistics, 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Genetics of biliary tract cancers and emerging targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

EGFR and HER2 expression in advanced biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Phase II study of erlotinib in patients with advanced biliary cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119993

5 July 2018

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.343

21 January 2018

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.343

21 January 2018

Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.343

21 January 2018

Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24960403

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China

1 reference

https://pubmed.ncbi.nlm.nih.gov/24960403

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exome sequencing of liver fluke-associated cholangiocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24960403

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24960403

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2014.343

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24960403%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33994406&oldid=1598235826"